Growth control mechanisms in multiple myeloma.

Abstract:

:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest brought about by type I (IFNs-alpha/beta) and type II (IFN-gamma) IFNs occurs in part through utilization/modification of various components of the otherwise stimulatory Jak-STAT and Ras signaling pathways triggered by IL-6. Recent experimental results indicating that IFN-alpha acts as a survival factor for certain myeloma cell lines and frequently induces endogenous IL-6 expression may help to explain the conflicting clinical findings obtained in this heterogeneous disease with this usually potent growth inhibitor. By comparison, consistent antiproliferative activity exhibited by IFN-gamma on IL-6-dependent myeloma cell lines and primary myeloma cells from patients suggests that further investigation of the possible value of this cytokine in the treatment of MM may be warranted.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Hawley RG,Berger LC

doi

10.3109/10428199809050906

subject

Has Abstract

pub_date

1998-05-01 00:00:00

pages

465-75

issue

5-6

eissn

1042-8194

issn

1029-2403

journal_volume

29

pub_type

杂志文章,评审
  • Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.

    abstract::Although current immunochemotherapy has increased the therapeutic efficacy in diffuse large B-cell lymphoma (DLBCL), there are still some patients who present unfavorable outcomes. Novel effective treatment strategies are needed to improve the prognosis of DLBCL. In this review, we discussed the functional mechanisms ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1691194

    authors: Wang M,Fang X,Wang X

    更新日期:2020-04-01 00:00:00

  • Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.

    abstract::The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly inc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209053608

    authors: Lauria F,Rondelli D,Raspadori D,Zinzani PL,Benfenati D,Pileri S,Sabattini E,Tura S

    更新日期:1992-05-01 00:00:00

  • The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.

    abstract::In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000003009

    authors: Sarkar S,Svoboda M,de Beaumont R,Freedman AS

    更新日期:2002-08-01 00:00:00

  • Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma.

    abstract::In this study cytogenetic findings have been correlated with prognosis in 78 previously untreated patients with non-Hodgkin's lymphoma (NHL) presenting between 1983 and 1988. The median follow-up was 7 years (range 2-9 years). There was no significant difference in the duration of survival of 33 patients with only abn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709039037

    authors: Juneja S,Matthews J,Lukeis R,Laidlaw C,Cooper I,Wolf M,Ironside P,Garson OM

    更新日期:1997-05-01 00:00:00

  • Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.

    abstract::The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509051698

    authors: Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

    更新日期:1995-03-01 00:00:00

  • R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.

    abstract::Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. In this retrospective study, we evaluated changes in vertebral bone density (VD) in DLBCL patients by measuring CT-ascertained Hounsfield units (HU) at the L3 level. In total, 111 patients dia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1233543

    authors: Svendsen P,Shekhrajka N,Nielsen KL,Vestergaard P,Poulsen MØ,Vistisen AK,Munksgaard PS,Severinsen MT,Jensen P,Johnsen HE,Jakobsen LH,Bøgsted M,Frøkjær JB,El-Galaly TC

    更新日期:2017-05-01 00:00:00

  • Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.

    abstract::The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000030054

    authors: Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

    更新日期:2003-02-01 00:00:00

  • Daratumumab for the treatment of AL amyloidosis.

    abstract::Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1485914

    authors: Sidiqi MH,Gertz MA

    更新日期:2019-02-01 00:00:00

  • Lymphomatous proptosis as a novel feature of mantle cell lymphoma.

    abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500301058

    authors: Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

    更新日期:2006-01-01 00:00:00

  • Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.

    abstract::The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001663572

    authors: Cohen KA,Liu TF,Cline JM,Wagner JD,Hall PD,Frankel AE

    更新日期:2004-08-01 00:00:00

  • Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.

    abstract::The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1791854

    authors: Tanasijevic AM,Revette A,Klepin HD,Zeidan A,Townsley D,DiNardo CD,Sebert M,DeZern AE,Stone RM,Magnavita ES,Chen R,Sekeres MA,Abel GA

    更新日期:2020-12-01 00:00:00

  • Detection of respiratory viruses with a multiplex polymerase chain reaction assay (MultiCode-PLx Respiratory Virus Panel) in patients with hematologic malignancies.

    abstract::Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902777665

    authors: Murali S,Langston AA,Nolte FS,Banks G,Martin R,Caliendo AM

    更新日期:2009-04-01 00:00:00

  • Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study.

    abstract::The role of malnutrition at diagnosis as a predictor of early mortality in Mexican leukemia children remains controversial. The objective of present study was to investigate whether malnutrition was a predictor of early mortality during the first year of treatment in Mexican acute lymphoblastic leukemia (ALL) children...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2016.1219904

    authors: Martín-Trejo JA,Núñez-Enríquez JC,Fajardo-Gutiérrez A,Medina-Sansón A,Flores-Lujano J,Jiménez-Hernández E,Amador-Sanchez R,Peñaloza-Gonzalez JG,Alvarez-Rodriguez FJ,Bolea-Murga V,Espinosa-Elizondo RM,de Diego Flores-Chapa J,Pérez

    更新日期:2017-04-01 00:00:00

  • Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.

    abstract::Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.836598

    authors: Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

    更新日期:2014-06-01 00:00:00

  • Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.

    abstract::Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.704034

    authors: Bashash D,Ghaffari SH,Mirzaee R,Alimoghaddam K,Ghavamzadeh A

    更新日期:2013-03-01 00:00:00

  • Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.

    abstract::Renal involvement in patients with lymphoma is rare but associated with poor prognosis. We analyzed characteristics and outcome of 22 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and renal involvement treated with a rituximab-containing regimen in curative intent. The majority of patients presen...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1157869

    authors: Lehners N,Krämer I,Schwarzbich MA,Ho AD,Witzens-Harig M

    更新日期:2016-11-01 00:00:00

  • Transcobalamin II and in vitro proliferation of leukemic cells.

    abstract::We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809050933

    authors: McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

    更新日期:1998-06-01 00:00:00

  • Gravin gene expression in acute leukaemias: clinical importance and review of the literature.

    abstract::The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701377055

    authors: Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

    更新日期:2007-06-01 00:00:00

  • Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells.

    abstract::We have evaluated the severe combined immunodeficient (SCID) mouse as an in-vivo model for the study of non-Hodgkin's lymphomas (NHL). Characterization of the immune system of the animals in our SCID mouse colony was carried out to assess the numbers of lymphoid cells present, to determine natural killer (NK) cell act...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609054785

    authors: Zubair AC,Ali SA,Rees RC,Goepel JR,Winfield DA,Goyns MH

    更新日期:1996-08-01 00:00:00

  • Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro.

    abstract::Genistein is one of the major isoflavones in soy products. It has been reported that genistein has apoptotic effects on certain hematological malignancies. However, so far there have been no completely comparative studies of the effect of genistein on malignant hematological diseases, especially multiple myeloma. We i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.598251

    authors: Li W,Frame LT,Hoo KA,Li Y,D'Cunha N,Cobos E

    更新日期:2011-12-01 00:00:00

  • Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.

    abstract::HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760011

    authors: Burke LP,Kukoly CA

    更新日期:2008-02-01 00:00:00

  • Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

    abstract::One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701836852

    authors: Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

    更新日期:2008-03-01 00:00:00

  • Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

    abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1251592

    authors: Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

    更新日期:2017-06-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006260

    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00

  • Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.

    abstract::It is now known that syngeneic transplantation, T lymphocyte depletion and absence of graft-versus-host disease all increase the risk of relapse following allogeneic transplantation for the myeloid leukemias, both acute and chronic. Leukemia-specific immune responses appear to play a major role in the therapy of the m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309067922

    authors: Rowe JM,Nilsson BI,Simonsson B

    更新日期:1993-11-01 00:00:00

  • Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.

    abstract::Whole-blood three-color immunofluorescence analysis was used to investigate the role of CD5/CD72 and CD21/CD23 receptor-ligand pair formation on B-chronic lymphocytic leukemia (B-CLL) cells as well as sCD23 and bcl-2 oncoprotein expression in disease progression and activity and total tumor mass in B-cell chronic leuk...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709114169

    authors: Gagro A,Dasić G,Sabioncello A,Rabatić S,Reckzeh B,Havemann K,Kardum I,Jacksić B,Vitale B

    更新日期:1997-04-01 00:00:00

  • Possible immortalization of Hodgkin and Reed-Sternberg cells: telomerase expression, lengthening of telomere, and inhibition of apoptosis by NF-kappaB expression.

    abstract::Telomerase, an enzyme associated with cellular immortality, is expressed on malignant tumor cells. Deregulation of telomerase is thought to facilitate tumorigenesis and cellular immortality by providing cancer cells with unlimited proliferation capacity. Hodgkin and Reed-Sternberg (H&RS) cells are generally considered...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109057992

    authors: Ohshima K,Sugihara M,Haraoka S,Suzumiya J,Kanda M,Kawasaki C,Shimazaki K,Kikuchi M

    更新日期:2001-04-01 00:00:00

  • Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

    abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1457147

    authors: Pleyer C,Wiestner A,Sun C

    更新日期:2018-12-01 00:00:00

  • Bone marrow transplantation in hemophagocytic lymphohistiocytosis.

    abstract::Two important syndromes of hemophagocytic lymphohistiocytosis (HLH) have to be considered in infants and young children with recurrent fever, organomegaly and cytopenias. Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infil...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057957

    authors: Dürken M,Finckenstein FG,Janka GE

    更新日期:2001-03-01 00:00:00

  • Rituximab therapy in monoclonal IgM-related neuropathies.

    abstract::Monoclonal IgM-related neuropathies constitute a heterogeneous group of disorders, which are generally poorly responsive to treatment. Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside act...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/14786410500441664

    authors: Kilidireas C,Anagnostopoulos A,Karandreas N,Mouselimi L,Dimopoulos MA

    更新日期:2006-05-01 00:00:00